2 results
Approved WMOPending
Primary ObjectivesSafety run-in Part 1:To confirm the recommended dose of alpelisib in combination with trastuzumab and pertuzumab for Part 2.Double-blind, randomized, placebo-controlled Part 2:To determine whether treatment with alpelisib in…
Approved WMORecruiting
To determine the activity and safety of nivolumab (as monotherapy or in combination with other immunomodulatory treatments) after different immune response induction treatments in TNBC patients with metastatic disease.